NEWAMSTERDAM PHARMA CO NV (NAMS)
NL00150012L7 - Common Stock
NEWAMSTERDAM PHARMA CO NV
NASDAQ:NAMS (12/20/2024, 8:26:28 PM)
After market: 25.5 0 (0%)25.5
+0.04 (+0.16%)
Company Profile
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. The company is headquartered in Naarden, Noord-Holland and currently employs 62 full-time employees. The company went IPO on 2022-11-23. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The firm is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The firm is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The firm strives to offer its products around the world.
Company Info
NEWAMSTERDAM PHARMA CO NV
Gooimeer 2-35
Naarden NOORD-HOLLAND
P: 31352062971
Employees: 57
Website: https://ir.newamsterdampharma.com/
NAMS News
5 days ago - Menarini Industrie Farmaceutiche RiuniteMenarini Group gibt positive Topline-Daten aus den klinischen Phase-3-Studien BROADWAY und TANDEM zur Bewertung von Obicetrapib und der Fixkombination Obicetrapib mit Ezetimib 10 mg bekannt- Beide entscheidenden Studien erreichten die primären Endpunkte der mittleren Senkung des LDL-Cholesterins zusätzlich zu maximal verträglichen lipidsenkenden...
5 days ago - Menarini Industrie Farmaceutiche RiuniteMenarini Group annonce des données de base positives issues des essais cliniques pivots de phase 3 BROADWAY et TANDEM qui évaluent l'Obicetrapib et l'association à dose fixe d'Obicetrapib et d'Ézétimibe 10 mg– Les deux études pivot s ont atteint les critères d'évaluation primaires de réduction moyenne par les moindres carrés (LS) du LDL-C en plus des thérapies de...
5 days ago - Menarini Industrie Farmaceutiche RiuniteMenarini Group anuncia datos positivos de los ensayos clínicos fundamentales de fase 3 BROADWAY y TANDEM– Menarini Group anuncia datos positivos de los ensayos clínicos fundamentales de fase 3 BROADWAY y TANDEM que evalúan obicetrapib y la combinación de dosis...
6 days ago - Menarini Industrie Farmaceutiche RiuniteMenarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical...
8 days ago - NewAmsterdam Pharma N.V.NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares8 days ago - NewAmsterdam Pharma N.V.NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a...
NAMS Twits
Here you can normally see the latest stock twits on NAMS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
